Clinical trial
Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic…
NCT00206726 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00206726 |
|---|---|
| Title | Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL) |
| Official title | Phase II Study Using Alemtuzumab Combined With Fludarabine for the Treatment of Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL) |
| Acronym | ECO-1 |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphocytic, Chronic, B-Cell |
| Intervention type | Drug |
| Interventions | Alemtuzumab plus Fludarabine |
| Enrollment | 60 |
| Start date | May 1, 2005 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Sep 21, 2005 |
| Last update posted | Aug 29, 2016 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: